Predictive Efficacy of Haematological Biomarkers in COVID-19 infection

  • Nadeem Ikram RMU
  • Asma Nafisa
  • Rabia Anjum
Keywords: COVID‐19

Abstract

Introduction: The ongoing Corona Virus Pandemic is linked with high rates of morbidity and mortality globally. Early and effective predictors of clinical outcomes are urgently required to develop effective management protocols.
Objective: To investigate the predictive efficacy of haematological biomarkers in Covid -19 infection
Methods: Blood samples were drawn from COVID‐19 infected pneumonia patients. Baseline clinical information was collected and quantification of hemostatic variable was done.  Laboratory data both groups expired and recovered were compared using t- test, Mann Whitney- U test, chi squared-test and Kruskal Wallis test. Multivariate regression analysis was performed to determine the independent contribution of haematological variable in Covid19 related mortality. Receiver operating characteristic curve were drawn to find the predictive efficacy of significantly related parameters.
Results: Out of 191 patients 68.1%  were male. D‐dimer (median 800 ng/mL; IQR 200‐3200) and NLR (median 10.40; IQR 3.20-22.80) were found to be predominantly raised and significantly correlated with Covid mortality in multivariate regression analysis. The optimum cutoff value of D-dimer to predict in-hospital mortality was 450 ng/ml with a sensitivity of 71.6% and a specificity of 95.8%. The optimum cutoff value of NLR to predict in-hospital mortality was 5.450 with a sensitivity of 70.1% and a specificity of 71%.
Conclusion: D-dimer and NLR could be used as the significant indicators in predicting the mortality of COVID-19.

References

1. Liao D, Zhou F, Xu M, Wang H, Xia J. Haematological characteristics and risk factors in the classification and prognostic evaluation of COVID-19. Lancer, 2020;10.1016/82352-3026(20).30217-19
2. Aggarwal M , Dass J, Mahapatra M. Haemostatic abnormalities in COVID- 19 : An update. Indian Hematol Blood Transfus, 2020 ; 36(4): 616–626.
3. Guan W, Ni Z, Hu Y, Liang WH. Clinical characteristics of Corona virus disease 2019 in China. N Eng J Med, 2020; 382:1708-20
4. Bikedli B, MAdhavan MV, Jimenaz D, Chuich T. COVID-19 and thrombotic or thrombo-embolic disease:implications for prevention and thrombotic therapy and follow – up. J Am Coll Cardiol, 2020; 20:35008-017
5. Lagnhas-Rangel FA. Neutrophil to lymphocyte ratio and lymphocyte to –C-reactive protein ratio in patients with severe corona virus disease. Journal of Med Virol, 2020;92:733-36
6. Ghahramanni S, Tabrizi R, Lankarani KB, Kashani MA, Rezaei S. Laboratory features of severe versus non-severe COVID- 19 patients in Asian population . Eur j Med Res, 2020;25:30-39.
7. Usul E, Sau I, Bekgoz B, Sahin A. The role of hematological parameters in COVID-19 patients in the emergency room. Biomark Med,2020;10.2217/bmm-0317
8. Khartabil TA, Russchert H, vanderVen A, Rijke B. A summary of the diagnosti and prognostic value of hemocaytaometro – markers in COVID-19 patients. Critical Reviews in Clinicla Lab Sciences, 2020 57(6)415-31
9. Weikove R, Quilten Z, Adler J. Haemotology and oncology COVID-19 interim guidance version 3.0.Hematol Soc Aust New Zeal, 2020; https://www.hsanz.org.an
10. Ranucci M, Ballota A, Dedda U, Bayshnikova E, Poli M. The pro-coagulant pattern of patients with COVID-10 acute respiratory distress syndrome. J Thromb haemost, 2020; 18: 1747-51
11. Caricchio R, Gallucci M, Dass C. Preliminary predictive criteria for COVID-19 cytokine storm. Ann Rheum Dis , 2020; doi:10-1136/ 218323
12. Tang N, Li D,Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel corona virus pneumonia. Journal of Thrombosis and Hhaemostasis, 2020. 18(4): 844-47
13. Kiok FA, Kruip MJ, vander Meer NJM. Incidence of thrombosis in patients with severe SARS-CoV-2 infection:a multicenter prospective cohort study. Intensive Care med,2020;46:1089-94
14. Khidar L, Gendron N, Gondot G, Chocron R. Curative anticoagulation prevents endothelial lesions in COVID-19 pateints . J Thromb haemost , 2020;18:2391-99
15. Bosolo A,Spiezia L, Correale C, Sella N, Pesenti E. Different hyerpcoagualable profiles in patients with COVID-19 admitted to the internal medicine ward and the intensive care unit. Thromb haemost, 2020;120:1474-77
16. - Chen N, Zhou M, Dong X, Qu J. Epidemiological and clinical characteristics of 99 cases of 2019 novel corona virus pneumonia . Lancet, 2020;395(2020):507-13.
17. - Zhang L, Yan X, Fan Q, Liu H. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19 . J Thromb Haemost, 2020; 10: 14859-62
18. - Panigade M, Bottino N, Tagliabue P, Grasselli G. Hypercoagulability of COVID-19 patients in intensive care unit ; a report of thromboelstography findings and other paremeters of hemostasis. J Thromb Haemost, 2020; 111:14850-54
19. Helms J,Tacquard C, Severac F. High risk of thrombosis in patients with severe SARS-CoV-2 infection : a multicenter prospective cohort study. Intensive Care Med,2020;46:1089-98.
20. Pimental GD. Vega DM, laviano A. High neutropgil-to-lymphocyte ratio as a prognostic marker in COVID-19 patients in Asian population. Eur J Med Res, 2020;25; 30-39
21. Huang J, Cheng A, Lin S. Individulized prediction monograms for disease progression in mild COVID-19 . J med Virol, 2020; DOI:10,1002/jmv.25969
22. Hu L, Chan S, Fu Y. Risk factors associated with clinical outcomes in 323 COVID-19 patients . Clin Infect Dis 2020; DOI:10.1101/ 03.25.20037721
23. Ye W, Chen G, Li X, Lau X, Ji C. Dynamic changes of D-dimer and neutrophil –lymphocyte ratio as prognostic biomarkers in COVID-19. Respiratory Research ,2020; 21: 169-75
24. Fan BE, Chia YW, Sum CL, Kuperan P. Global haemostatic tests in rapid diagnosis and management of COVID-19 associated coagulopathy. Journal of Thrombosis and Thrombolysis 2020; 50: 292-97
25. Zhou F, Yu T, DuR. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan ,China. Lancet, 2020; 395(10229): 1054-62
26. Di Minno MND, Calcaterra I, Lupoli R, Storino A, Spedicato GA. Hemostatic changes in patients with COVID-19: a meta-analysis with meta-regressions. Journal of clinical medicine, 2020. 9(7): p. 2244.
27. Huang C, Wang Y, LiPX, Ren PL. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 2020. 395(10223): 497-506.
28. Yao Y,Cao J, Wang Q1, Shi Q, Liu K, Luo Z, Chen X D-dimer as a biomarker for disease severity and mortality in COVID-19 patients: a case control study. Journal of intensive care, 2020. 8(1): 1-11.
29. Zuo Y, Talavartnis S, Shi H. Neutrophil extracellular traps in COVID-19 . JC Insight, 2020; 5(11): 138999
30. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. Journal of Thrombosis and Thrombolysis, 2020;10.1007/s11239-020-02105-08
31. Zhang B, Zhou X, Qiu y. Clinical characeteristics of 82 death cases with COVID-19 . Med Rxiv, 2020; DOI:10;1101/2020.02.26.20028191
32. Lodigiani C, Iapichino G, Carenzo L. Venous and arterial thrombo-embolic complications in COVID-19 patients admitted to an academic hospital in Milan , Italy. Thromb Res, 2020;191:9-14
33. Zhou F,YuT, DuR, Fan G, Liu Y. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet, 2020; 395: 1054–62
34. Thachil J, Srivastva A. SARS-2 corona virus –associated hemostatic lung abnormality in COVID-19 :is it pulmonary thrombosis or pulmonary embolism . Semin Thromb Hemost, 2020; 10: 2155-59
35. Blasi A,Meinjenfeldt FA, Adelmeijer J, Calvo A. In-vitro hypercoagulability and ongoing in vivo activation of coagulation and fibrinolysis in COVD-19 patients . J Thromb haemost, 2020;18(10):https://doi.org/10.1111/jth.15043
36. Adam EH, Zacherowski K, Miesbach W. A comprehensive assessment of coagulation profile in critically ill COVID-19 pateints. Thrombosis Research , 2020; 194: 42-44
37. Weiss E , RonxO, Mayer JD, Burtz CP, Bondaond L. Fibrinolysis resistance : A potential mechanism underlying COVID-19 coagulopathy. Thromb Haemost,2020;120:1343-45
38. Yang X,Yang Q, Wang Y, Wu Y. Thrombocytopenia and its association with morality in patients with COVID-19 .J Thromb Haemost, 2020; 10: 14848-52
39. XuP.Zhou Q, XuJ. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol, 2020;99;1205-08
40. Spiezia L,Boscolo A, Poletto F, Ceruti L. COVDI-19 related severe hypercoagulability in patients admitted to intensive care unit from acute respiratory failure . Thromb Haemost, 2020;120:998-1000
41. Savioli F. Coagulation profile in severe COVID- 19 patients : What do we know sofar? Rev Bras ter Intensiva,2020;32(2): 197-99
42. Fu J, Kong J, Wang W, Wu M, Yao L, Wang Z,Fu, J.The clinical implication of dynamic neutrophil to lymphocyte ratio and D-dimer in COVID-19: A retrospective study in Suzhou China. Thrombosis Research, 2020; 192: 3–8
43. Lin Y, Du X, Chen J, Jin Y, Peng L, Wang HX. Neutrophil – to – lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. Journal of Infection,2020;81:e6-e12
44. Qin C, Zhou L , Hu Z , Zhang S, Yang S, Tao Y.Qin Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clinical Infectious Diseases, 2020;71(15):762-68
45. Bai, Y., Yao L,Wei T, Presumed asymptomatic carrier transmission of COVID-19. JAMA, 2020. 323(14): p. 1406-1407.
46. Alfaraj SH, Al-tawfiq JA, Assiri AY, AlzahraniNA. Clinical predictors of mortality of Middle East Respiratroy Syndrome corona virus infection –A cohort study. Travel Med Infect Dis,2019;29:48-50
47. Lin J , Lin Y, Xiang P. Neutrophil –to-lymphocyte ratio predicts critical illness patients with 2019 corona virus disease in the early stage . J Transl Med, 2020;18(1)206- 09;https://doi.org/10.1186/s12967-020-02374-0
48. Yang AP, Liu JP, Tao W, LiH. The diagnostic and predictive role of NLR, d-NLR and PLR I COVID-19 patients . International Immuno-Pharmacology ,2020;84:106504
49. Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-2019 infection. Clin Chem Lab Med,2020;DOI: 10.1515/ cclm-2020-0198
50. Heinz BM . COVID-19 and lymphopenia ; a word of caution. Lancet Respir Med, 2020;8:e24
51. Kong M,Zhang H, Cao X, Mao X, LuZ. Higher level of neutrophil –to- lypmohcyte is associated with severe COVID-19 . Epidemiology and Infection, 2020;148:e139;1-6
52. Bermejo – Martin JF,Almansa R, Menendez R,Kelvin DJ. Lymphopenic community acquired pneumonia as signature of severe COVID-19 infection. J Infect, 2020;80(5):23-27
53. Ghahramanni S, Tabrizi R, Lankarani KB, Kashani MA, Rezaei S. Laboratory features of severe versus non-severe COVID- 19 patients in Asian population . Eur j Med Res, 2020;25:30-39.
54. Wang Y, Lu X, Chen H. Clinical course and outcomes of 344 intensive care patients with COVID-19. Am J Respir Crit Care Med, 202; DOI:10.1164/rccm.202003-0736LE
Published
2020-12-30
How to Cite
1.
Ikram N, Nafisa A, Anjum R. Predictive Efficacy of Haematological Biomarkers in COVID-19 infection. JRMC [Internet]. 30Dec.2020 [cited 24Sep.2021];24(4):423-9. Available from: https://journalrmc.com/index.php/JRMC/article/view/1517